Search results
Shareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past week
Simply Wall St. via Yahoo Finance· 3 days agoWe think intelligent long term investing is the way to go. But along the way some stocks are going...
Nuvectis Pharma exec buys shares worth over $7,000 By Investing.com
Investing.com· 2 days agoIn a recent transaction on May 10, 2024, Shay Shemesh, the Chief Development & Operations Officer at...
In trial over cancer claims, pharma executive questioned about proper storage, handling of Zantac
Chicago Sun-Times· 4 hours agoThe attorneys representing a woman suing the drug makers behind Zantac continued to make the case...
Pharma Exec Sells Hillsboro Beach Mansion at a Loss for $19M
The Real Deal· 1 day agoRaymond Mirra Jr., a pharma executive and ex-husband of convicted killer Gigi Jordan, sold his...
Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
Simply Wall St. via Yahoo Finance· 4 days agoRegular readers will know that we love our dividends at Simply Wall St, which is why it's exciting...
Nuvectis Pharma CEO acquires $12.8k in company stock By Investing.com
Investing.com· 2 days agoIn a recent move that signals confidence in Nuvectis Pharma, Inc. (NASDAQ:NVCT), CEO and Chairman...
Innate Pharma (IPHA) to Release Earnings on Tuesday
ETF DAILY NEWS· 2 days agoInnate Pharma (NASDAQ:IPHA – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 14th. Individual interested in registering ...
FDA extends review of Ascendis Pharma's hormone disorder therapy
Reuters via Yahoo Finance· 7 hours agoMay 14 (Reuters) - The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder, the company said ...
Royalty Pharma Beats Q1 Earnings and Revenue Estimates - Royalty Pharma (NASDAQ:RPRX), Atlanticus...
Benzinga· 5 days agoRoyalty Pharma RPRX came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus...
Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men...
WKRN Nashville· 2 days agoSumitomo Pharma America, Inc. (SMPA), announced today the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for vibegron (GEMTESA ...